2/24
10:04 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/24
10:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.
2/24
09:11 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
2/24
07:18 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/24
07:01 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/24
07:00 am
axsm
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
Medium
Report
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
2/23
06:01 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/23
03:59 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $200.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $200.00 price target on by analysts at Truist Financial Corporation.
2/23
03:59 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $215.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $215.00 price target on by analysts at Jefferies Financial Group Inc..
2/23
02:03 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/23
12:54 pm
axsm
Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/23
11:22 am
axsm
Why The Axsome Therapeutics (AXSM) Story Is Shifting As Analysts Rework Valuation Models [Yahoo! Finance]
Low
Report
Why The Axsome Therapeutics (AXSM) Story Is Shifting As Analysts Rework Valuation Models [Yahoo! Finance]
2/23
08:37 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
2/23
07:00 am
axsm
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/22
06:13 pm
axsm
Here are the major earnings before the open Monday [Seeking Alpha]
Medium
Report
Here are the major earnings before the open Monday [Seeking Alpha]
2/19
09:16 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $230.00 price target on by analysts at Mizuho.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $230.00 price target on by analysts at Mizuho.
2/18
07:30 am
axsm
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/18
07:00 am
axsm
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/18
12:32 am
axsm
Axsome Therapeutics (AXSM) Valuation After SUNOSI Patent Settlement Extends Generic Entry Timeline [Yahoo! Finance]
Low
Report
Axsome Therapeutics (AXSM) Valuation After SUNOSI Patent Settlement Extends Generic Entry Timeline [Yahoo! Finance]
2/17
07:00 am
axsm
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
Low
Report
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
2/4
03:25 pm
axsm
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
Low
Report
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
2/3
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.
2/3
07:13 am
axsm
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]
Low
Report
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]
1/29
10:04 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/28
02:29 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.